NCT07168668View on ClinicalTrials.gov

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

May 30, 2028

Conditions
HCCTaceImmunotherapy
Interventions
PROCEDURE

Transarterial chemoembolization

"1. Targeting 1-3 prognostically relevant tumor nodules.~2. Administration of anti-cancer drugs (doxorubicin 20 mg in each section of TACE).~3. Embolization with Drug-Eluting Beads (doxorubicin 20 mg loaded Hepasphere 20 mg of TACE)~4. Embolization was done when there was a slight decrease in blood flow for each tumor feeder."

DRUG

durvalumab and tremelimumab

Combine TACE with immunotherapy

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT07168668 - Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment | Biotech Hunter | Biotech Hunter